Evidence map›Paper›PMID 22110136›Full record

ArticleThe Journal of biological chemistry2012

Structural basis for the recognition of C20:2-αGalCer by the invariant natural killer T cell receptor-like antibody L363.

Esther Dawen Yu, Enrico Girardi, Jing Wang, Thien-Thi Mac, Karl O A Yu, Serge Van Calenbergh, Steven A Porcelli, Dirk M Zajonc

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Frontiers in immunology · 2017
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Activation of iNKT cells by a distinct constituent of the endogenous glucosylceramide fraction.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Esther Dawen YuDivision of Cell Biology, La Jolla Institute for Allergy & Immunology, La Jolla, California 92037, USA.
Enrico Girardi
Jing Wang
Thien-Thi Mac
Karl O A Yu
Serge Van Calenbergh
Steven A Porcelli
Dirk M Zajonc
La Jolla Institute for Immunology · USAlbert Einstein College of Medicine · USGhent University · BE

Funding

Precision Targeting of CD1-Restricted iNKT Cells for Cancer ImmunotherapyR01AI045889 · NIAID · YESHIVA UNIVERSITY · PI Steven A Porcelli · 1999 to 2026
$9.3M
Structural Immunology of CD1 and CD1-TCR ComplexesR01AI074952 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI ZAJONC, DIRK M · 2009 to 2013
$1.8M
Structural Immunology of CD1 and CD1-TCR ComplexesR56AI074952 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI ZAJONC, DIRK M · 2008 to 2008
$412k
NIAID NIH HHS AI074952NIAID NIH HHS AI45889NIAID NIH HHS R01 AI045889NIAID NIH HHS R01 AI074952NIAID NIH HHS R56 AI074952
6 · The paper itself

Abstract

Natural killer T (NKT) cells express a semi-invariant Vα14 T cell receptor (TCR) and recognize structurally diverse antigens presented by the antigen-presenting molecule CD1d that range from phosphoglycerolipids to α- and β-anomeric glycosphingolipids, as well as microbial α-glycosyl diacylglycerolipids. Recently developed antibodies that are specific for the complex of the prototypical invariant NKT (iNKT) cell antigen αGalCer (KRN7000) bound to mouse CD1d have become valuable tools in elucidating the mechanism of antigen loading and presentation. Here, we report the 3.1 Å resolution crystal structure of the Fab of one of these antibodies, L363, bound to mCD1d complexed with the αGalCer analog C20:2, revealing that L363 is an iNKT TCR-like antibody that binds CD1d-presented αGalCer in a manner similar to the TCR. The structure reveals that L363 depends on both the L and H chains for binding to the glycolipid-mCD1d complex, although only the L chain is involved in contacts with the glycolipid antigen. The H chain of L363 features residue Trp-104, which mimics the TCR CDR3α residue Leu-99, which is crucial for CD1d binding. We characterized the antigen-specificity of L363 toward several different glycolipids, demonstrating that whereas the TCR can induce structural changes in both antigen and CD1d to recognize disparate lipid antigens, the antibody L363 can only induce the F' roof formation in CD1d but fails to reorient the glycolipid headgroup necessary for binding. In summary, L363 is a powerful tool to study mechanism of iNKT cell activation for structural analogs of KRN7000, and our study can aid in the design of antibodies with altered antigen specificity.

Indexed as

Amino Acid SequenceAnimalsAntibodies, Monoclonal, Murine-DerivedAntibody SpecificityAntigens, CD1dCrystallography, X-RayGalactosylceramidesImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsMiceMolecular Sequence DataNatural Killer T-CellsProtein Structure, QuaternaryReceptors, Antigen, T-Cell, alpha-betaAntibodies, Monoclonal, Murine-DerivedAntigens, CD1dCd1d1 protein, mouseGalactosylceramidesImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsKRN 7000Receptors, Antigen, T-Cell, alpha-beta

Identifiers

PMID22110136
PMCPMC3256878
OpenAlexW2060237390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.